XTX Topco Ltd Invests $29,000 in Cara Therapeutics, Inc. (NASDAQ:CARA)

XTX Topco Ltd bought a new stake in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) during the 3rd quarter, HoldingsChannel reports. The firm bought 94,709 shares of the biopharmaceutical company’s stock, valued at approximately $29,000.

Separately, Disciplined Growth Investors Inc. MN raised its stake in shares of Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 120,660 shares during the period. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of Cara Therapeutics in a report on Monday. They set a “sell” rating for the company. One analyst has rated the stock with a sell rating and five have issued a hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $2.32.

Cara Therapeutics Trading Up 3.4 %

Cara Therapeutics stock opened at $0.42 on Monday. The stock has a 50 day moving average of $0.29 and a 200-day moving average of $0.32. The stock has a market cap of $23.18 million, a P/E ratio of -0.24 and a beta of 0.64. Cara Therapeutics, Inc. has a 52 week low of $0.23 and a 52 week high of $1.15.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.